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MicroRNAs (miRNAs) are a class of 21- to 25-nucleotide non-coding RNAs, some of which are impor-
tant gene regulators involved in folliculogenesis. In this study, we used CCK-8, real-time PCR and
Western blot assays to demonstrate that miR-145 inhibits mouse granulosa cell (mGC) proliferation.
Combined with the results of luciferase reporter assays that studied the 30-untranslated region of
ACVRIB mRNA, these assays identiﬁed ACVRIB as a direct target of miR-145. The ectopic expression
of miR-145 reduced the levels of both ACVRIB mRNA and protein and also interfered with activin-
induced Smad2 phosphorylation. Altogether, this study revealed that miR-145 suppresses mGC pro-
liferation by targeting ACVRIB.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Previous studies have shown that follicles, the functional units
of the ovary, consist of a central oocyte surrounded by one or more
layers of somatic granulosa cells (GCs). Folliculogenesis is a com-
plex process during which oocytes increase in size and develop
into a mature form, accompanied by the proliferation and differen-
tiation of the surrounding granulosa cells [1–3]. The pituitary
gonadotropins FSH and LH play an important role in stimulating
folliculogenesis during follicular development. This process is also
regulated by various extra- and intraovarian factors such as activ-
ins, inhibins, BMPs and GDF-9 [4–6].
Activins belong to the transforming growth factor b (TGF-b)
superfamily, are made up of two subunits (bA and bB) and are clas-
siﬁed into three types: activin A (bAbA), activin B (bBbB) and acti-
vin AB (bAbB) [7]. Increasing evidence suggests that activins arechemical Societies. Published by E
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rk.involved in reproductive dysfunction and cancer, and that they
apparently play important roles in the regulation of folliculogene-
sis and follicular function [8–11]. Activins have been shown to pro-
mote the maturation of oocytes and regulate the proliferation of
GCs, and the different expression of TGF-b proteins (such as inhi-
bins, activins and follistatin) imply a signiﬁcant functional role
for these peptides in the development of follicles within the ovary
[12–14].
The two types of activin receptors that have intrinsic serine/
threonine kinase activity are designated as type I (ACVRIA and
ACVRIB) and type II (ACVRIIA and ACVRIIB). Activin binds directly
to the type II activin receptor, leading to the phosphorylation and
activation of the type I activin receptor (also known as ALK4). Acti-
vated ALK4 transiently interacts with and phosphorylates two
intracellular signal transducers, Smad2 and Smad3 (R-Smads),
which, upon phosphorylation, form complexes with the common
partner Smad4 (Co-Smad). Subsequently, the Smad complexes
translocate into the nucleus and bind to the promoters of target
genes to regulate their expression [15–17].
MicroRNAs (miRNAs) are a class of 21- to 25-nucleotide non-
coding RNAs that have been recognized as important gene regula-
tors. miRNAs function as regulators of gene expression by targeting
mRNAs for degradation or blocking mRNA translation by binding to
the 30-untranslated region (30-UTR) [18,19]. Hundreds of miRNAs
have been identiﬁed and shown to participate in the regulation
of various biological processes, such as cell proliferation, differen-
tiation and apoptosis [19–21]. For example, miR-145 is capable oflsevier B.V. All rights reserved.
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as c-Myc, mucin 1 and ER-alpha [22–24]. In addition, miR-145 tar-
gets pluripotency factors such as OCT4, SOX9 and ITGB8 and func-
tions as a key regulator of human stem cells [25–27]. Evidence
indicates that some miRNAs may play critical roles in controlling
the expression of genes that are essential for ovarian folliculogen-
esis and endocrine function [28,29], which suggests that miRNAs
may be important for follicular development. However, miRNAs
involvement in the regulation of ovarian function has not been
well documented.
Therefore, this study aimed to investigate the effects that miR-
145 have on mouse granulosa cell proliferation. In addition, ACV-
RIB was identiﬁed as a miR-145 target that may be mediated in
the process of regulating mouse granulosa cell proliferation.
2. Materials and methods
2.1. Animals
Three-week-old ICR mice were purchased from the Lab Animal
Center of Yangzhou University (Yangzhou, China) and maintained
in the Animal Laboratory Center of Drum Tower Hospital (Nanjing,
China) on a 12:12 h light/dark cycle (lights off at 19:00) with food
and water available ad libitum. All of the experiments involving
animals were performed according to the guidelines of the Exper-
imental Animal Management Committee (Jiangsu Province, China).
2.2. Cell lines
HEK293 cells and HEK293A cells were maintained in DMEM/
High Glucose (Gibco BRL/Invitrogen, Carlsbad, CA, USA) supple-
mented with 10% fetal bovine serum (FBS, Gibco BRL/Invitrogen,
Carlsbad, CA, USA) and antibiotics (100 IU/ml penicillin and
100 lg/ml streptomycin, Gibco BRL/Invitrogen, Carlsbad, CA,
USA). The cells were kept at 37 C in a humidiﬁed environment
with 5% CO2.
2.3. Mouse primary granulosa cell collection and culture
Mouse granulosa cells (mGCs) were collected from the ovaries
of 21-day-old immature ICR mice using the follicle puncture meth-
od, as described previously [30]. The mGCs were cultured in
DMEM/F12 (Gibco BRL/Invitrogen, Carlsbad, CA, USA) supple-
mented with 10% FBS, 1% sodium pyruvate (Gibco BRL/Invitrogen,
Carlsbad, CA, USA), 1% glutamine (Gibco BRL/Invitrogen, Carlsbad,
CA, USA), 100 IU/ml penicillin, and 100 lg/ml streptomycin in
the presence or absence of activin A (R&D Systems, Minneapolis,
MN, USA). The cells were incubated at 37 C and supplemented
with 5% CO2 in a humidiﬁed chamber.Table 1
DNA sequences of primers used for real-time PCR.
Genes Primers(50–3) Products size (bp)
miR-145 CGCGCTCGAGCCCAGAGCAATAAGCCACAT
GGTGTCGTGGAGTCGGCAATTCAGTTGAG
69
U6 CTCGCTTCGGCAGCACA
AACGCTTCACGAATTTGCGT
94
mCCND2 ACACCGACAACTCTGTGAAGC
GCCAGGTTCCACTTCAGCTTA
79
mACVRIB GCTTGCATGGTCTCCATCTT
GGGACCCTGAGGTCAATCTT
176
m18S rRNA ATGGCCGTTCTTAGTTGGTG
CGGACATCTAAGGGCATCAC
1832.4. Construction of recombinant adenovirus
Adenoviruses harboring a 441-bp DNA fragment encompassing
the has-miR-145 gene (Ad-miR-145), Flag-tagged mouse ACVRIB
without 30-UTR (Ad-ﬂag-mACVRIB), Flag-tagged mouse ACVRIB
with wild-type 30-UTR (Ad-ﬂag-mACVRIB-30-UTR) and ﬂag-tagged
mouse ACVRIB with 30-UTR-mutant (Ad-ﬂag-mACVRIB -30-UTR
mu) were generated using the AdMax (Microbix) system according
to the manufacturer’s recommendations. The adenovirus bearing
LacZ (Ad-LacZ) was obtained from Clontech. The viruses were
packaged and ampliﬁed in HEK293A cells and puriﬁed using CsCl
banding followed by dialysis against 10 mM Tris-buffered saline
with 10% glycerol. The viral titer was determined using HEK293A
cells and the Adeno-X Rapid Titer kit (BD Biosciences Clontech,
Palo Alto, CA, USA) according to the manufacturer’s instructions.2.5. Cell proliferation assays
The cell proliferation assays were conducted using a Cell Count-
ing Kit-8 (CCK-8, Dojindo Laboratories, Kumamoto, Japan) accord-
ing to the manufacturer’s instructions. The cells were seeded in 96-
well plates at approximately 0.5–1  104 cells per well and cul-
tured in growth medium. The level of cellular proliferation was de-
tected 48 h after treatment with Ad-miR-145 or the miR-145
inhibitor (Ribobio, Guangzhou, China). A 10-ll aliquot of CCK-8 re-
agent was added to each well, and the plates were then incubated
for 1–3 h. The cell numbers were detected on a microplate reader
by measuring the absorbance at 450 nm (OD450).
2.6. RNA isolation and quantitative real-time PCR
Total RNA was isolated from tissues and cultured cells using Tri-
zol reagent (Invitrogen, Carlsbad, CA, USA). cDNA was synthesized
from 1 lg of puriﬁed RNA using a PrimeScript RT reagent kit (Bio-
Rad Laboratories, Hercules, CA, USA) according to the manufac-
turer’s protocol. The speciﬁc primers used for the quantitative
polymerase chain reaction (PCR) analysis are listed in Table 1. Each
sample was analyzed in triplicate, and the experiment was re-
peated three times. Each real-time PCR reaction was composed of
1 ll RT product, 10 ll SYBR Green PCR Master Mix (Bio-Rad Labo-
ratories, Hercules, CA, USA), and 500 nM forward and reverse prim-
ers. The real-time PCR was performed on a MyiQ Single Color Real-
time PCR Detection System (Bio-Rad Laboratories, Hercules, CA,
USA) in 40 cycles (miRNAs: 95 C for 15 s, 60 C for 1 min after
an initial 15 min incubation at 95 C. Genes: 95 C for 10 s, 60 C
for 30 s, 72 C for 30 s after an initial 3 min incubation at 95 C).
The data were analyzed with the 2-DDCTmethod [31], and the fold
changes in gene expression were normalized to 18S rRNA or U6 as
endogenous controls.
2.7. Western blotting
Total protein was isolated from mGCs, which were harvested at
48 h after treatment. The cells were rinsed with ice-cold PBS (pH
7.4) and lysed with whole cell lysis buffer (50 mM Tris–HCl pH
7.6, 150 mM NaCl, 1.0% NP-40, Protease Inhibitor Cocktail, Phos-
phatase Inhibitor Cocktail (Sigma, St. Louis, MO, USA)). The protein
concentrations were determined by a Bradford assay (Bio-Rad Lab-
oratories, Hercules, CA, USA). Equal amounts of total protein
(30 lg) were separated on a 10% SDS–polyacrylamide gel, trans-
ferred to a polyvinylidene ﬂuoride (PVDF) membrane (Millipore,
Billerica, MA, USA), incubated with antibodies, and visualized using
a chemiluminescence detection kit (Amersham Biosciences Corp.,
Piscataway, NJ, USA). The following antibodies were used for
immunoblotting: anti-phospho-Smad2 (1:800, Cell Signaling Tech-
nology, Danvers, MA, USA), anti-Smad2 (1:1000, Cell Signaling
Technology, Danvers, MA, USA), anti-cyclin D2 (1:500, Cell Signal-
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Technology Inc. Minneapolis, MN, USA), anti-Flag (1:2000, Invitro-
gen, Carlsbad, CA, USA), anti-Smad4 (1:500, Bioworld Technology
Inc. Minneapolis, MN, USA), anti-b-actin (1:5000, Sigma, St. Louis,
MO, USA) Goat anti-rabbit (1:5000, Bio-Rad Laboratories, Hercules,
CA, USA) and goat anti-mouse (1:10000, Bio-Rad Laboratories, Her-
cules, CA, USA) secondary antibodies were used.
2.8. Transient transfection and luciferase reporter assay
Based on the mouse ACVRIB mRNA sequence (accession No.
NM_007395.3) and mouse CCND2 mRNA sequence (accession No.
NM_009829.3) deposited in the GenBank database, the ﬁre lucifer-
ase cDNA fused with the 30UTR fragments of mouse ACVRIB mRNA
(694nt, 549–1242) and the mouse CCND2 mRNA (726nt, 2684–
3589) containing the putative miR-145 binding site were ampliﬁed
separately from mGCs cDNA and cloned into the region down-
stream of the ﬁreﬂy luciferase gene in the pGL3-promoter lucifer-
ase reporter vector (Promega, Madison, USA) and the resulting
plasmid was sequenced to conﬁrm its identity. Preconﬂuent (75–
80%) HEK293 cells in 12-well plates were transfected with the
appropriate plasmids using the NanoFectin transfection reagent
(PAA, Pasching, Austria). The Renilla luciferase reporter plasmid
pRL-RSV (Promega, Madison, WI, USA) was included as a control
for transfection efﬁciency. After 48 h, the cells were harvested
and lysed for use in the luciferase reporter assay, which was per-
formed using the Luciferase Assay System (Promega, Madison,
WI, USA) and measured with a Centro XS3 LB 960 luminescence
counter (Berthold Technologies, GmbH Co. KG, Germany). At least
three transfection assays were performed to obtain statistically
signiﬁcant data.Fig. 1. The effect of miR-145 on mGC proliferation. Mouse granulosa cells were infected
for 48 h. (A and C) miR-145 expression increased in a dose-dependent manner after infec
(B and D) Result of a Cell Counting Kit-8 assay examining the proliferation of mouse gr
control group.2.9. Statistical analysis
All experiments were repeated at least three times, and the data
are expressed as the mean ± S.E.M. The Student’s t-test was used
for statistical comparisons. P values less than 0.05 were considered
statistically signiﬁcant.
3. Results
3.1. MiR-145 inhibits mouse granulosa cell proliferation
We successfully produced 8.91  1010 ifu/ml Ad-miR-145 in
the laboratory and examined miR-145 expression in mGCs after
treatment with Ad-miR-145 or the miR-145 inhibitor. As ex-
pected, miR-145 expression increased after infection with Ad-
miR-145 and decreased after transfection of the miR-145 inhibi-
tor. Both of these effects were dose-dependent (Fig. 1A and
C).miR-145 has been reported to inhibit tumor cell growth and
invasion [22–24], so we investigated whether miR-145 plays a
role in the proliferation of mGCs. We ﬁrst found that the prolifer-
ation of mGCs was dose-dependently suppressed after infection
with Ad-miR-145, but increased upon transfection with a miR-
145 inhibitor (Fig. 1B and D). Because cyclin D2 (CCND2) is an
important protein in the cell cycle [32], we also investigated
the expression of CCND2 in mGCs after treatment with Ad-miR-
145 or the miR-145 inhibitor. As shown in Fig. 2C and E, the re-
sults indicate that the overexpression of miR-145 decreased both
the mRNA and protein levels of CCND2 in mGCs. Furthermore, the
miR-145 inhibitor enhanced the mRNA and protein expressions of
CCND2 (Fig. 2D and F).with Ad-miR-145 or transfected with miR-145 inhibitor at the MOI or nM indicated
tion with Ad-miR-145, but was reduced after transfection of the miR-145 inhibitor.
anulosa cells. ⁄, P < 0.05, compared with Ad-LacZ group; #, P < 0.05, compared with
Fig. 2. MiR-145 directly inhibits expression of CCND2 via its 30UTR. Putative binding sites for mouse miR-145 in the 30UTR of CCND2 mRNA, seed match region was shown in
brown and seed mutant region was shown in red. (B) mGCs were transfected with or without miR-145, and mouse CCND2 gene 30UTR luciferase activity was inhibited by
miR-145, but had no effect on the activity of luciferase fused with CCND2 30UTR mutant. ⁄, P < 0.05, compared with control. (C and E) CCND2 mRNA expression and protein
level in mouse granulosa cells was down-regulated by overexpression of miR-145, ⁄, P < 0.05, compared with Ad-LacZ group. (D and F) CCND2 mRNA expression and mRNA
expression and protein level in mouse granulosa cells was examined after treated with the miR-145 inhibitor at the nM indicted for 48 h through qRT-PCR and Western blot.
#, P < 0.05, compared with control.
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their 30UTR
MiR-145 has been reported to regulate target gene expression
through direct binding to the 30-untranslated region (30-UTR) of
target mRNAs [18,19]. Thus, we used the online miRNA target gene
prediction program miRanda (http://www.miRbase.org/) to iden-
tify candidate target genes for miR-145, and found that CCND2
and ACVRIB are potential miR-145 targets (Figs. 2A and 3A).
Accordingly, we constructed a luciferase reporter plasmids con-
taining the 30UTR region of mouse CCND2 and ACVRIB with the
putative miR-145 binding site. After overexpression of miR-145
in mGCs, luciferase activity was indeed decreased signiﬁcantly
(Figs. 2B and 3B). In contrast, overexpression of miR-145 had no ef-
fect on the activity of luciferase gene fused with the CCND2 and
ACVRIB 30-UTR mutant (Figs. 2B and 3B). To conﬁrm the result,
we also generated adenoviruses harboring Flag-ACVR1B with the
30UTR of ACVR1B gene, then co-infected with Ad-miR-145 in
mouse granulosa cells. As showed in Fig. 3C, overexpression miR-
145 suppressed the Flag-tagged ACVR1B expression, but when
co-infected with ACVR1B without its 30UTR and mutant sequence,
miR-145 had no effect on Flag-ACVR1B expression. Moreover, qRT-
PCR results showed that the CCND2 and ACVRIB mRNA level de-
creased when mGCs were infected with Ad-miR-145 (Figs. 2C
and 3D), but increased when the cells were treated with themiR-145 inhibitor (Figs. 2D and 3E). To further verifyCCND2 and
ACVRIB as a target of miR-145, we performed Western blot analy-
sis to look at the expression of endogenous CCND2 and ACVR1B in
mGCs transduced with Ad-miR145. As shown in Figs. 2E and 3F, in
a dose-dependent manner, overexpressing miR-145 markedly
inhibited endogenous CCND2 and ACVR1B expression, and the
expression of CCND2 and ACVRIB protein was stimulated by the
miR-145 inhibitor (Figs. 2F and 3G). All of these data indicate that
miR-145 targets CCND2 and ACVRIB by binding to their 30-UTR.
3.3. MiR-145 inhibits activin A-induced mGC proliferation
Activin A is an important regulator of follicle development and
can promote granulosa cell proliferation [8,12,13]. As described
above, we showed that miR-145 inhibited the proliferation of
mGC. Therefore, we further investigated whether miR-145 plays
a role in activin A-inducedmGC proliferation. First, we investigated
the level of miR-145 in mGCs after treatment with activin A (50 ng/
ml) for 48 h, ﬁnding that activin A signiﬁcantly reduced the expres-
sion of miR-145 (Fig. 4A). We conﬁrmed that activin A increased
the expression of CCND2mRNA and protein, as reported previously
[32]. Moreover, our results showed that the overexpression of miR-
145 decreased the activin A-induced increase in CCND2 mRNA and
protein levels in mGCs (Fig. 4B and C). We also investigated the le-
vel of miR-145 in mGCs 48 h after treatment with activin A (50 ng/
Fig. 3. MiR-145 targets the ACVR1B in mouse granulosa cells. (A) Putative binding sites for mouse miR-145 in the 30UTR of ACVR1B mRNA and its seed sequence mutant were
shown in red. (B) HEK293 cells were transfected with or without miR-145, and mouse ACVR1B gene 30UTR luciferase activity was inhibited by miR-145, but had no effect on
the activity of luciferase fused with ACVR1B 30UTR mutant. ⁄, P < 0.05, compared with control. (C) Adenoviruses harboring Flag-ACVR1B with or without the 30UTR of ACVR1B
gene were co-infected with Ad-miR-145 in mouse granulosa cells 48 h later, the ACVR1B expression was immunoblotted with horseradish peroxidase (HRP)-conjugated anti-
Flag antibody. (D and E) ACVR1B mRNA expression in mouse granulosa cells was down-regulated by overexpression of miR-145 and was increased by miR-145 inhibitor. ⁄,
P < 0.05, compared with control. (F and G) Endogenous ACVR1B protein level in mouse granulosa cells was examined after treated with the Ad-miR-145 and miR-145
inhibitor at the concentration indicted for 48 h through Western blot.
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miR-145 (Fig. 4C). These data suggest that miR-145 modulates
activin A-induced mGC proliferation.
3.4. MiR-145 inactivates the intracellular activin-induced Smad
signaling pathway
To characterize the function of miR-145 in the activin-induced
Smad signaling pathway, we investigated the expression and phos-
phorylation of Smad2 in mGCs by Western blot. The results
showed that activin A treatment (50 ng/ml) signiﬁcantly increased
the level of phosphorylated Smad2 (Ser465/467) and that miR-145
treatment attenuated this effect. However, Smad2 expression per
se was not signiﬁcantly changed by the different treatments
(Fig. 4D). What’s more, neither activin A nor miR-145 had any ef-
fect on Smad4 expression.
3.5. MiR-145 inhibits mGC proliferation by targeting ACVRIB
To further substantiate that miR-145 inhibits granulosa cell
proliferation by targeting ACVR1B, we performed loss-of-function
studies using RNA interference (Fig. 5A and B). Although ACVRIB
knockdown in mGCs had a weak inhibiton of proliferation, when
the endogenous ACVRIB protein expression was inhibited, the pro-
motion of proliferation in mGCs by activin A was signiﬁcantly de-creased (Fig. 5C). As shown in Fig. 5D, overexpression of ACVRIB
increased the proliferation of mGCs apparently, importantly while
increased the expression of ACVRIB in mGCs could attenuate the
proliferation suppressing effects of overexpression miR-145. All
of these data suggest that miR-145 inhibits mGC proliferation by
targeting ACVRIB.
4. Discussion
Recently, many research groups have begun studying microR-
NAs, which target a variety of genes and have predictable charac-
teristics. Some miRNAs appear to play important roles in
regulating the expression of genes that are essential for ovarian fol-
liculogenesis and endocrine function [28,29]. Recent evidence has
shown that hundreds of miRNAs participate in the regulation of
various cellular processes, and miR-145 appears to be one such
regulatory miRNA. For example, miR-145 inhibits breast cancer cell
proliferation by targeting mucin 1 [23]. Thus, we hypothesized that
miR-145 might have an impact on the proliferation of mouse gran-
ulosa cells.
In addition, our previous microarray studies investigating the
expression proﬁles of plasma microRNAs have shown that miR-
145 expression is much higher in patients who experience prema-
ture ovarian failure (POF) than in women with normal ovarian
function (data not shown). POF is characterized by amenorrhoea,
Fig. 4. MiR-145 inhibits activin A-induced mGC proliferation and inactivates the intracellular activin Smad signaling pathway. (A) Mouse granulosa cells were cultured in
low-serum media (containing 2.5% c-FBS) and treated with 50 ng/ml activin A for up to 48 h. miR-145 expression was examined by qRT-PCR. ⁄, P < 0.05, compared with
untreated group. (B) qRT-PCR showed the mRNA level of CCND2 in mGCs infected with or without Ad-miR-145 in the presence or absence of activin A for 48 h. ⁄, P < 0.05. #,
P < 0.05. (C) Western blot showed the protein expression of CCND2 in mGCs infected with or without Ad-miR-145 in the presence or absence of activin A for 48 h. (D) Western
blot showed the protein expressions of Smad2 phosphorylation, Smad2 and Smad4 in mGCs infected with or without Ad-miR-145 in the presence or absence of activin A for
48 h.
Fig. 5. MiR-145 inhibits mGC proliferation by targeting ACVRIB.(A and B) qRT-PCR and Western blot showed expression of ACVR1B in mGCs transfected with si-CTL or si-
ACVR1B (50nM) for 3 days. ⁄, P < 0.05, compared with si-CTL group. (C) Mouse granulosa cells were transfected with 50 nM si-ACVR1B for 48 h. Cell Counting Kit-8 assay
examining the proliferation of mouse granulosa cells in the presence or absence of activin A for 24 h. ⁄, P < 0.05, compared with si-CTL alone; #, P < 0.05, compared with si-CTL
treated with activin A group. (D) Result of a Cell Counting Kit-8 assay examining the proliferation of mouse granulosa cells were infected with Ad-ﬂag-ACVR1B and/or Ad-
miR-145 for 48 h. #, P < 0.05, compared with Ad-ﬂag-ACVR1B and Ad-miR-145 alone.
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tions in women under 40 years of age. Most women with POFexperience follicle depletion or follicle dysfunction [33–35]. Folli-
culogenesis includes the maturation of oocytes and the prolifera-
G. Yan et al. / FEBS Letters 586 (2012) 3263–3270 3269tion and differentiation of their surrounding granulosa cells [1–3].
Therefore, this study may help us understand whether miR-145
plays a causative role in POF.
In this study, we have conﬁrmed that miR-145 inhibits the pro-
liferation of mGCs. Our luciferase assays demonstrated that ACV-
RIB is a target of miR-145 and that miR-145 down-regulates the
expression of ACVRIB mRNA and protein by targeting the 30-UTR
of ACVRIB mRNA. Furthermore, we found that miR-145 reduced
activin-mediated Smad2 phosphorylation and attenuated the tran-
scriptional response to activin. It is known that activin binds to the
type II activin receptor directly, activating ACVRIB and the down-
stream Smad signaling pathway to regulate the expression of tar-
get genes [15–17]. Our Western blot results showed that Smad2
was phosphorylated as an immediate response to activin A. How-
ever, neither Smad2 nor Smad4 protein expression was signiﬁ-
cantly changed by the different treatments, and no Smad3
phosphorylation was detected after any of the treatments. Previous
studies have shown that activin A can speciﬁcally promote the
phosphorylation and nuclear translocation of Smad2 but not
Smad3 [36]. This difference may be because Smad2 and Smad3
have different Smad4 binding sites [37,38]. In addition, activin A
signiﬁcantly reduced the expression of miR-145, and the overex-
pression of miR-145 attenuated the function of activin A. This re-
sult suggests that miR-145 inhibits mGC proliferation maybe
partly by targeting ACVRIB directly. Further studies are needed to
address the precise molecular mechanisms involved in miR-145
inhibits activin A induced mGC proliferation.
Cyclin D proteins, including cyclin D1, cyclin D2, and cyclin
D3, are cell cycle activators and previous researches showed that
cyclin D1 and cyclin D3 in ovarian follicles were mainly expressed
in theca cells, while cyclin D2 was speciﬁcally localized in granu-
losa cells as an important regulator inducing their G1/S phase
transition [39]. Activin has been demonstrated to activate cyclin
D2 transcription through its signaling pathway [40]. Our lucifer-
ase assays and Western blot results showed that miR-145 targets
CCND2 directly by binding to its 30-UTR. What’s more, CCND2
protein level was decreased after the activin-induced Smad sig-
naling pathway was blocked by si-Smad2, and this suppression
was attenuated by miR-145 inhibitor (data not shown). These
data indicate that CCND2 is regulated by miR-145 directly and
indirectly in mGCs.
In summary, our study suggests that miR-145 inhibits the pro-
liferation of mGCs by targeting the 30-UTR of ACVRIB mRNA. This
study provides new insights into how miR-145 functions in the fe-
male reproductive system. Understanding the crosstalk between
miR-145 and mGC proliferation helps us understand the mecha-
nisms underlying follicle growth, which is a key process in the
pathology of POF. This study has provided a new potential target
for the diagnosis and treatment of POF. It will be important to
investigate these ﬁndings further in future studies.
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